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Introduction
Endothelial dysfunction is an initial step in the process of atherosclerosis and plays a critical role in the development of this condition, leading to cardiovascular complications. [1] In addition, endothelial function has been shown to be an independent predictor of cardiovascular events. [2, 3] Therefore, there is considerable research interest in the assessment of endothelial function for risk stratification in subjects with cardiovascular risk factors. Recently, flow-mediated vasodilation (FMD), a vascular dilatory response of the brachial artery to reactive hyperemia, has been widely used for the assessment of endothelial function in humans. [4] [5] [6] [7] Nitroglycerine-induced vasodilation (NID), a vascular dilatory response of the brachial artery to administered nitroglycerine, has been used as a control test for FMD measurement to confirm that the vascular dilatory response to reactive hyperemia is not affected by underlying vascular smooth muscle dysfunction or vascular structural alterations but is truly a consequence of endothelium-dependent vasodilation. [8, 9] However, recent studies have shown that NID per se is impaired in patients with multiple cardiovascular risk factors or a history of cardiovascular disease (CVD). [10] [11] [12] Moreover, we recently reported that impaired NID is associated with a higher incidence of cardiovascular events. [13] These findings suggest that NID in the brachial artery can be used not only as a diagnostic marker but also as a prognostic marker of atherosclerosis.
Chronic kidney disease (CKD) is an independent predictor of cardiovascular events. It has been reported that patients with end-stage renal disease (ESRD) have a much higher incidence of cardiovascular death than that in the general population and that cardiac disease is the leading cause of death in patients on chronic dialysis. [14] [15] [16] Recent studies have also shown that non-ESRD CKD is independently associated with an increased risk of cardiovascular mortality and cardiovascular events. [17, 18] It has been shown that endothelial function assessed by FMD in the brachial artery is significantly impaired in patients with CKD, especially in patients with ESRD, compared with that in subjects without CKD, although it is controversial whether CKD is independently associated with FMD. [19] [20] [21] [22] [23] As for the relationship between CKD and NID, it has been shown that NID is significantly impaired in patients with ESRD compared with that in subjects without ESRD. However, the relationship between non-ESRD CKD and NID has not been fully investigated. Although measurement of NID in patients with non-ESRD CKD was performed as a control test in several studies, previous studies were limited to small numbers of or highly selected subjects. [19] [20] [21] [22] [23] [24] In addition, it has not been determined whether non-ESRD CKD is independently associated with NID. We therefore investigated the relationship between non-ESRD CKD and NID in a large number of well-characterized subjects with or without CKD.
Methods

Subjects
Between April 2007 and April 2017, a total of 2743 subjects were recruited for measurement of vascular function from subjects who underwent health-screening examinations or who visited the outpatient clinic at Hiroshima University Hospital. Of the 2743 subjects, 1862 subjects underwent measurement of both FMD and NID of the brachial artery. Subjects who had received nitrate treatment (n=112) and chronic hemodialysis (n=23), subjects with estimated glomerular filtration rate (eGFR) <15 (G4). [29] The ethical committees of our institutions approved the study protocol. This study was performed in accordance with the Declaration of Helsinki. Written informed consent for participation in the study was obtained from all subjects.
Study protocol
We measured vascular responses to reactive hyperemia and sublingually administered nitroglycerine in the brachial artery. The subjects fasted the previous night for at least 12 hours. The subjects were kept in the supine position in a quiet, dark, air-conditioned room (constant temperature of 22°C to 25°C) throughout the study. A 23-gauge polyethylene catheter was inserted into the left deep antecubital vein to obtain blood samples. FMD was measured thirty min after maintaining the supine position. After completion, we next measured NID with confirmation that the brachial artery diameter had recovered to the baseline value. The observers were blind to the form of examination.
Measurement of FMD and NID
Vascular response to reactive hyperemia in the brachial artery was used for assessment of endothelium-dependent FMD. A high-resolution linear artery transducer was coupled to computer-assisted analysis software (UNEXEF18G, UNEX Co, Nagoya, Japan) that used an automated edge detection system for measurement of brachial artery diameter.
A blood pressure cuff was placed around the forearm. The brachial artery was scanned longitudinally 5 to 10 cm above the elbow. When the clearest B-mode image of the anterior and posterior intimal interfaces between the lumen and vessel wall was obtained, the transducer was held at the same point throughout the scan by a special probe holder (UNEX Co) to ensure consistency of the image. Depth and gain setting were set to optimize the images of the arterial lumen wall interface. When the tracking gate was placed on the intima, the artery diameter was automatically tracked, and the waveform of diameter changes over the cardiac cycle was displayed in real time using The response to nitroglycerine was used for assessment of endothelium-independent vasodilation. After acquiring baseline rest images for 30 s, a sublingual tablet (75 μg nitroglycerine) was given, and images of the artery were recorded continuously until the dilation reached a plateau after administration of nitroglycerine. We carefully checked in the mouth to confirm that tablet had been dissolved and absorbed a few minutes after administration of nitroglycerine. Subjects in whom the sublingually administered nitroglycerine tablet was not dissolved during the measurement were excluded from this study. NID was automatically calculated as a percent change in peak vessel diameter from the baseline value. Percentage of NID [(Peak diameter -Baseline diameter)/Baseline diameter] was used for analysis.
Statistical analysis
Results are presented as means±SD. All reported probability values were 2-sided, and a probability value of <0.05 was considered statistically significant. Categorical variables were compared by means of chi-square test. Continuous variables were compared by using unpaired Student's t test. Univariate linear regression analyses were performed to assess the relationships between NID, FMD, and eGFR. Multiple logistic regression analyses were performed to identify independent variables associated with vascular smooth muscle dysfunction and endothelial dysfunction. The data were processed using JMP version 11 (SAS institute, Cary, NC).
Results
Baseline clinical characteristics
The baseline clinical characteristics are summarized in Table 2 .
Relationship between CKD and NID
Univariate regression analysis revealed that eGFR was significantly correlated with NID When subjects were categorized into 3 groups according to the number of prescribed antihypertensive drugs (0, 1, and ≥2), the prevalence of endothelial dysfunction increased significantly in relation to increase in the number of prescribed antihypertensive drugs (15.5%, 24.8%, and 33.6%, P<0.001). The prevalence of endothelial dysfunction was significantly higher in subjects with CKD than in those without CKD in subjects without antihypertensive drug treatment (20.0% vs. 9.6%, P=0.04), whereas there was no significant difference in the prevalence of endothelial dysfunction between subjects with and without CKD in subjects treated with 1 antihypertensive drug (27.9% vs. 25.9%, P=0.68) and those treated with ≥2
antihypertensive drugs (36.8% vs. 37.3%, P=0.91).
Discussion
In the present study, we demonstrated that eGFR was positively correlated with NID and FMD and that the prevalence of vascular smooth muscle dysfunction and endothelial dysfunction was significantly higher in patients with CKD than in those without CKD. CKD was independently associated with vascular smooth muscle dysfunction even after multivariable adjustment, whereas the association between CKD and endothelial dysfunction was no longer significant after adjustment for age and sex.
To our knowledge, this is the first report showing that non-ESRD CKD is associated with vascular smooth muscle dysfunction.
It is well known that patients with ESRD have high rates of cardiovascular morbidity and mortality. The rate of cardiovascular mortality has been reported to be 10 to 20-times higher in patients treated by dialysis than in the general population even after stratification for age, sex, race, and diabetes mellitus. [30] Recent studies have shown that risks of cardiovascular events are higher not only in patients with ESRD but also in patients with CKD not undergoing maintenance dialysis and that CKD is an independent risk factor for CVD. [16, 17, 31] The association between CKD and endothelial function assessed by FMD has been investigated. [19] [20] [21] [22] [23] However, there is little information on the relationship between CKD and NID.
NID, a vasodilatory response of the brachial artery to sublingual nitroglycerine administration, is usually assessed as a control test for FMD in the brachial artery to confirm that the vasodilatory response of the brachial artery to reactive hyperemia is not affected by vascular smooth muscle dysfunction or structural alterations but is truly a consequence of endothelium-dependent vasodilation. However, several investigators, including us, have recently demonstrated that NID per se is impaired in patients with multiple cardiovascular risk factors or established CVDs, such as coronary artery disease, peripheral artery disease, and heart failure with preserved ejection fraction. [10] [11] [12] [32] [33] [34] [35] In addition, impaired NID in the brachial artery has been shown to be associated with a significantly higher incidence of cardiovascular events. [13] Therefore, not only FMD but also NID in the brachial artery could be a useful marker for risk stratification in subjects with cardiovascular risk factors.
Measurement of NID was performed in several studies in which the relationship between CKD and vascular function was investigated. [19] [20] [21] [22] [23] [24] NID has been shown to be significantly impaired in patients with ESRD compared to that in patients without CKD. [22, 24] However, the relationship between non-ESRD CKD and NID has not been fully investigated. It is unclear whether non-ESRD CKD is independently associated with NID since the relationship between non-ESRD CKD and NID was not evaluated because of the small number of subjects or highly selected subjects in previous studies. In the present study, we demonstrated that NID was significantly smaller in patients with non-ESRD CKD than in those without non-ESRD CKD and that non-ESRD CKD was independently associated with vascular smooth muscle dysfunction in a large number of well-characterized subjects with or without CKD.
Traditional cardiovascular risk factors, such as older age, hypertension, diabetes mellitus and dyslipidemia, tend to be highly prevalent as underlying diseases in patients with CKD. Indeed, in the present study, patients with CKD were older than patients without CKD and they had a higher prevalence of hypertension, dyslipidemia, and diabetes mellitus. These traditional cardiovascular risk factors have been shown not only to cause renal function impairment but also to be associated with impaired NID in the brachial artery. [10, 12] Therefore, impairment of NID in patients with CKD might be in part attributed to these coexisting traditional cardiovascular risk factors. However, in the present study, the association between CKD and vascular smooth muscle dysfunction remained significant even after adjustment for these traditional risk factors.
In addition, the prevalence of vascular smooth muscle dysfunction was significantly higher irrespective of the status of diabetes mellitus or antihypertensive drug treatment.
These findings suggest that CKD is not merely a marker for traditional CVD risk factors but a risk factor independently associated with vascular smooth muscle dysfunction.
Non-traditional risk factors associated with reduced renal function may contribute to the vascular smooth muscle dysfunction in patients with CKD, although WBC count, a measure of inflammation, was not associated with NID in the present study.
The Framingham Heart Study showed that there was no significant difference in FMD between subjects with non-ESRD CKD and those without non-ESRD CKD in either an age-and sex-adjusted model or a multivariable-adjusted model in a large community-based population, though NID was not assessed in that study. [36] Consistent with those previous observations, our results also showed that the association between endothelial dysfunction and non-ESRD CKD was no longer significant in either an age-and sex-adjusted model or a multivariable-adjusted model, though FMD was positively correlated with eGFR and was significantly smaller in patients with CKD than in those without CKD in unadjusted analysis. Non-traditional risk factors associated with reduced renal function, such as enhanced oxidative stress, may theoretically contribute not only to vascular smooth muscle dysfunction but also to endothelial dysfunction in patients with non-ESRD CKD. [37] However, in the present study, CKD was independently associated with vascular smooth muscle dysfunction but not with endothelial dysfunction. Although we do not know the precise reason for the difference in the association of CKD with vascular smooth muscle dysfunction and endothelial dysfunction, it might be due to the difference in the stage of atherosclerosis at which vascular smooth muscle dysfunction and endothelial dysfunction are initiated.
Endothelial dysfunction is the initial step in the process of atherosclerosis, and endothelial function assessed by FMD in the brachial artery is already impaired at an early stage of atherosclerosis. [1, 38] In addition, impairment of FMD has been shown to be an early event that precedes the impairment of NID. In conclusions, non-ESRD CKD is independently associated with vascular smooth muscle dysfunction but not with endothelial dysfunction. CKD is not merely a marker for traditional cardiovascular risk factors but is an independent risk factor associated with vascular smooth muscle dysfunction. Non-CKD CKD
